Hematologist
CION Cancer Clinics
IPSS-R risk scoring in MDS, explained | CION Cancer Clinics
The IPSS-R score places MDS into one of five risk groups. A score of 1.5 or less is very low risk, and above 6 is very high risk. It is built from five results: chromosome changes, blasts in the marrow, haemoglobin, platelets and neutrophils. The group guides how closely you are watched and which treatments are discussed. It is not a countdown. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does an IPSS-R score mean in MDS?
- Which results go into the IPSS-R score?
- Which risk group does my score fall into?
- How should you read your own score?
- What do people often misread about the IPSS-R score?
- How is IPSS-R different from the newer IPSS-M?
- What can a score not tell you?
- Common questions about the IPSS-R score
The short answer
What does an IPSS-R score mean in MDS?
The IPSS-R score places MDS into one of five risk groups, from very low to very high. A score of 1.5 or less is very low risk. A score above 6 is very high risk. The group guides how closely you are watched and which treatments are discussed.
What the letters stand for
IPSS-R is the Revised International Prognostic Scoring System. Prognostic means it describes how the disease is likely to behave. It was built by studying thousands of people with MDS and seeing which report findings went with slower or faster disease.
Why doctors use it
MDS behaves very differently from one person to the next. Two people with the same name on their report can need completely different plans. The score gives your haematologist a shared, tested way to sort that out. It also helps doctors compare notes when a second opinion is sought, and it is used to decide who can join clinical studies. For families, it turns a long, technical report into one plain idea: how active this MDS is likely to be.
What it is not
It is not a countdown. It describes large groups of people, not you. It was built mostly on people who had not yet had treatment, so it is most useful at diagnosis. It does not include your age, your heart or kidney health, or how you are coping day to day.
Newer scores such as IPSS-M add gene test results. Your report may mention one or both.Building the score
Which results go into the IPSS-R score?
Five findings from your blood and marrow tests each earn points. The points are added together to give the total.
Chromosome changes
The chromosome test on the marrow carries the most weight. Changes are sorted into five groups, from very good to very poor.
Example
- A normal result counts as good
- Many changes at once count as very poor
Blasts in the marrow
The share of very young cells. Up to 2% adds no points. The points rise at each step up to more than 10%, where they are highest.
Haemoglobin
Haemoglobin is measured in g/dL. A level of 10 or more adds no points. From 8 up to 10 adds some. Below 8 adds the most for this factor.
Platelets
A platelet count of 100 or more (in thousands per microlitre) adds no points. Lower counts add points, with the most below 50.
Neutrophils
Neutrophils are the white cells that fight bacteria. A count below 0.8 (in thousands per microlitre) adds a small number of points.
Not sure whether this applies to you?
Ask an oncologistThe five groups
Which risk group does my score fall into?
- Very low: 1.5 or less
- The gentlest pattern. Often managed with regular blood tests and support only when needed.
- Low: above 1.5, up to 3
- Usually treated as lower-risk MDS, with a focus on symptoms and low counts.
- Intermediate: above 3, up to 4.5
- The middle group. Doctors weigh gene results, age and fitness to decide which path suits you.
- High: above 4.5, up to 6
- Usually treated as higher-risk MDS. Treatment aimed at the disease itself is discussed.
- Very high: above 6
- The fastest-moving pattern. Treatment is usually planned without delay, and a transplant may be discussed for fit patients.
With your report in hand
How should you read your own score?
Find the five inputs
Look for the chromosome result, blast percentage, haemoglobin, platelets and neutrophils. If the chromosome result is missing, the score cannot be complete yet.
Check the dates
The blood counts should come from around the time of the marrow test. A count from a day after a transfusion can make the score look better than it is.
Note the group, not only the number
Treatment choices follow the group. A score that sits right at the edge of two groups is worth asking about.
Ask what else is being weighed
Gene changes, age, other illnesses and your own wishes all shape the plan alongside the score.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do people often misread about the IPSS-R score?
"The score tells us exactly how long he has."
It does not. The score describes how groups of people fared in studies, some of them many years ago. Treatments have changed since. One person can do far better or worse than the group average.
"Our score is low, so we can stop the check-ups."
MDS can change over time. A low score today is a reason for calmer, regular follow-up, not for no follow-up. Your counts are how a change is caught early.
"If the haemoglobin improves after a transfusion, the score goes down."
The score is meant to use counts from before treatment. A transfusion lifts the haemoglobin for a while without changing the disease. Doctors take this into account.
"A high score means treatment is pointless."
A high score is exactly when treatment is most often offered. It shapes which options are discussed, not whether help is possible.
Two scores, side by side
How is IPSS-R different from the newer IPSS-M?
IPSS-R
IPSS-M
Uses blood counts, blasts and chromosomes
Adds results from a panel of gene tests
Five risk groups
Six risk groups, with the middle split in two
Widely used and easy to work out
Needs gene testing, which is not always available
Being straight with you
What can a score not tell you?
A score cannot tell you how you will feel, how treatment will suit you, or how long anyone will live. It is one tool, used at one point in time, to help plan care.
Laboratories and single results
Reference ranges differ between laboratories. A single blood result can be thrown off by an infection, bleeding or a recent transfusion. Your haematologist reads each number alongside your symptoms and repeat tests before trusting the score. If a result looks out of line with how you feel, it is fair to ask whether the test should be repeated.
What to ask your haematologist
Ask for the score and the group written down. Ask which of the five inputs drove it most. Ask whether gene testing would change the group. Ask how often the score will be looked at again. At CION the haematology team reviews the full set of reports and presents the case at a tumour board before a plan is confirmed.
If the score frightens you, bring that worry to the appointment. It is a fair question to ask what the number means for your next few months.Questions we are asked
Common questions about the IPSS-R score
Can the IPSS-R score change?
Yes. The score was designed for use at diagnosis, but the disease can change. If counts fall, blasts rise or new chromosome changes appear on a repeat test, your haematologist may work out the score again. A change in group can lead to a change in the plan.
My report shows no IPSS-R. Should I be worried?
Not necessarily. The score is usually worked out by the treating haematologist, not the laboratory. It also needs the chromosome result, which often arrives later than the rest. Ask at your appointment whether the score has been calculated and what group it gives.
Can I calculate the score myself online?
Online calculators exist, but they are easy to misuse. Chromosome results are hard to sort correctly without training, and a count taken after a transfusion gives a wrong answer. It is safer to ask your haematologist to go through the score with you.
Does age change the IPSS-R group?
Age is not one of the five inputs. Doctors do take it into account alongside the score, because age and fitness affect how well someone copes with each treatment. An age-adjusted version exists, but most treatment decisions use the standard groups plus a clinical judgement.
What does "intermediate risk" mean for treatment?
It is the group where decisions depend most on other factors. Some people are treated like lower-risk MDS, others like higher-risk MDS. Gene results, how low the counts are and your fitness usually tip the balance. Ask which way your team is leaning and why.
Is IPSS-R used for CMML too?
Not usually. CMML has its own scoring systems, because it behaves differently from MDS. If your report mentions raised monocytes, ask whether the diagnosis is MDS or CMML, and which score was used.
Why is my chromosome result so important?
In the IPSS-R, chromosome changes carry more weight than any other single input. Some changes are linked with slow disease and others with fast disease. A failed or missing chromosome test can leave the score uncertain, so your team may repeat the marrow sample to get it.
Should we get a second opinion on the score?
A second opinion is reasonable when a big decision rests on the group, such as whether to plan a transplant. Bring the marrow report, chromosome and gene results, and blood counts from around the time of the marrow test. The CION helpline can tell you what else to bring.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Myelodysplastic syndromes: detection, diagnosis and staging
- National Cancer Institute — Myelodysplastic Syndromes Treatment (PDQ), Patient Version
- Cancer.Net — Myelodysplastic syndromes (MDS)
- Leukemia & Lymphoma Society — Myelodysplastic syndromes
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
MDS Explained: When the Marrow Stops Making Good CellsThe basics, if MDS is new to youLower-Risk MDS: Supportive Care and MonitoringWhat follows a very low or low scoreHigher-Risk MDS: Azacitidine and BeyondWhat follows a high or very high scoreMDS Life Expectancy by Risk GroupWhat affects the outlook, explained without false numbers
Talk to us
Have a score you do not understand?
Tell us what has been found so far. The haematology team will go through the reports with you and help you reach the right specialist. One helpline serves every CION centre.